P/E ratio for CymaBay Therapeutics (CBAY)
P/E ratio as of May 2024 (TTM): -36.9
According to CymaBay Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -36.9091. At the end of 2022 the company had a P/E ratio of -5.18.
P/E ratio history for CymaBay Therapeutics from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.18 | 94.7% |
| 2021 | -2.66 | -65.23% |
| 2020 | -7.65 | 497.43% |
| 2019 | -1.28 | -79.65% |
| 2018 | -6.30 | -45.25% |
| 2017 | -11.5 | 657.8% |
| 2016 | -1.52 | -29.96% |
| 2015 | -2.17 | -40.27% |
| 2014 | -3.63 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 14.9 | -140.35% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.0 | -129.82% | 🇺🇸 USA |
 Xencor XNCR | -11.0 | -70.08% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | -3.89 | -89.47% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.